Directory
Juan Verdaguer Autonell

Juan Verdaguer Autonell

Degree: PhD

973 702 210
joan.verdaguer(ELIMINAR)@udl.cat

Groups

Publications

  • Amrani, A; Serra, P; Yamanouchi, J; Han, BY; Thiessen, S; Verdaguer, J; Santamaria, P

    CD154-dependent priming of diabetogenic CD4(+) T cells dissociated from activation of antigen-presenting cells.

    Immunity 16 719-732. .

    [doi:10.1016/S1074-7613(02)00315-1]

  • Thiessen, S; Serra, P; Amrani, A; Verdaguer, J; Santamaria, P

    T-cell tolerance by dendritic cells and macrophages as a mechanism for the major histocompatibility complex-linked resistance to autoimmune diabetes.

    Diabetes 51 325-338. .

  • Amrani, A; Serra, P; Verdaguer, J; Yamanouchi, J; Thiessen, S; Santamaria, P

    Inactivation of islet antigen-presenting cells upon engagement of Peptide/MHC class II in the absence of CD40 ligation

    Diabetes 50 34-35. .

  • Amrani, A; Verdaguer, J; Serra, P; Tafuro, S; Tan, RS; Santamaria, P

    Progression of autoimmune diabetes driven by avidity maturation of a T-cell population.

    Nature 406 739-742. .

    [doi:10.1038/35021081]

  • Thiessen, S; Amrani, A; Verdaguer, J; Santamaria, P

    Central tolerance as a common mechanism of diabetes protection afforded by multiple anti-diabetogenic I-a and I-E molecules

    Diabetes 49 279-279. .

  • Amrani, A; Verdaguer, J; Serra, P; Tafuro, S; Tan, RS; Santamaria, P

    Progression from insulitis to diabetes driven by affinity maturation of a CD8+T cell population

    Diabetes 49 282-282. .

  • Amrani, A; Verdaguer, J; T'hiessen, S; Bou, S; Santamaria, P

    IL-1alpha, IL-1beta, and IFN-gamma mark beta cells for Fas-dependent destruction by diabetogenic CD4(+) T lymphocytes.

    JOURNAL OF CLINICAL INVESTIGATION 105 459-468. .

    [doi:10.1172/JCI8185]

  • Anderson, B; Park, BJ; Verdaguer, J; Amrani, A; Santamaria, P

    Prevalent CD8(+) T cell response against one peptide/MHC complex in autoimmune diabetes.

    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 96 9311-9316. .

    [doi:10.1073/pnas.96.16.9311]

  • Verdaguer, J; Amrani, A; Anderson, B; Schmidt, D; Santamaria, P

    Two mechanisms for the non-MHC-linked resistance to spontaneous autoimmunity.

    JOURNAL OF IMMUNOLOGY 162 4614-4626. .

  • Schmidt, D; Amrani, A; Verdaguer, J; Bou, S; Santamaria, P

    Autoantigen-independent deletion of diabetogenic CD4(+) thymocytes by protective MHC class II molecules

    JOURNAL OF IMMUNOLOGY 162 4627-4636. .

  • Amrani, A; Verdaguer, J; Anderson, B; Utsugi, T; Bou, S; Santamaria, P

    Perforin-independent beta-cell destruction by diabetogenic CD8(+) T lymphocytes in transgenic nonobese diabetic mice.

    JOURNAL OF CLINICAL INVESTIGATION 103 1201-1209. .

    [doi:10.1172/JCI6266]

  • Verdaguer, J; Schmidt, D; Amrani, A; Anderson, B; Averill, N; Santamaria, P

    Spontaneous autoimmune diabetes in monoclonal T cell nonobese diabetic mice.

    JOURNAL OF EXPERIMENTAL MEDICINE 186 1663-1676. .

    [doi:10.1084/jem.186.10.1663]

Projects

  • Estudio del impacto generado por modificaciones en la microbiota intestinal sobre la actividad del sistema inmune en el modelo murino NOD de diabetes autoinmune.
  • OncoNeoVac, un nuevo enfoque inmunoterapéutico para el tratamiento del melanoma.
  • INVESTIGO 2022: Grup de Recerca en Immunologia i Metabolisme (GRIM)
  • Modelación de la microbiota intestinal en las etapas iniciales del desarrollo de la diabetes autoinmune en el ratón NOD, modelo de la diabetes tipo 1 humana.
  • Estudi de l'efecte adjuvant de DIF-P en una vacuna antigripal
  • Linfocitos T y B anti-periferina y anti-cromogranina T and B lymphocyte durante el desarrollo de la Diabetes Mellitus Tipo 1 (APACT1D)
  • Linfocitos B y T autoreactivos en la diabetes del tipo 1: Análisis funcional y desarrollo de estrategias de tratamiento (BATINT1D)
  • CARACTERIZACIÓN DE LA RESPUESTA DE LINFOCITOS B AUTOREACTIVOS CONTRA UN NUEVO AUTOANTIGENO DE 90 KDA ESPECIFICO DE CELULAS BETA PANCREATICAS DURANTE EL DESARROLLO DE LA DIABETES TIPO 1
  • IDENTIFICACIO DEL NOU AUTOANTIGEN ICA85 I CARACTERITZACIO DE LA RESPOSTA AUTOINMUNITARIA CONTRA AQUEST EN PACIENTS AMB DIABETIS TIPUS 1